Your browser doesn't support javascript.
loading
Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer.
Augustinus, Simone; Schafrat, Pascale J M; Janssen, Boris V; Bonsing, Bert A; Brosens, Lodewijk A A; Busch, Olivier R; Crobach, Stijn; Doukas, Michail; van Eijck, Casper H; van der Geest, Lydia G M; Groot Koerkamp, Bas; de Hingh, Ignace H J T; Raicu, G Mihaela; van Santvoort, Hjalmar C; van Velthuysen, Marie-Louise; Verheij, Joanne; Besselink, Marc G; Farina Sarasqueta, Arantza.
Afiliación
  • Augustinus S; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. s.augustinus@amsterdamUMC.nl.
  • Schafrat PJM; Cancer Center Amsterdam, Amsterdam, The Netherlands. s.augustinus@amsterdamUMC.nl.
  • Janssen BV; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Bonsing BA; Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Brosens LAA; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Busch OR; Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Crobach S; Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Doukas M; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • van Eijck CH; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van der Geest LGM; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Groot Koerkamp B; Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • de Hingh IHJT; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Raicu GM; Department of Pathology, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • van Santvoort HC; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • van Velthuysen ML; Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
  • Verheij J; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Besselink MG; Department of Surgery, Catherina Hospital, Eindhoven, The Netherlands.
  • Farina Sarasqueta A; Department of Pathology, St Antonius Hospital and Pathology DNA, Nieuwegein, The Netherlands.
Ann Surg Oncol ; 30(8): 5051-5060, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37210448
BACKGROUND: Surgeons aim for R0 resection in patients with pancreatic cancer to improve overall survival. However, it is unclear whether recent changes in pancreatic cancer care such as centralization, increased use of neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting have influenced R0 resections and whether R0 resection remains associated with overall survival. METHODS: This nationwide retrospective cohort study included consecutive patients after pancreatoduodenectomy (PD) for pancreatic cancer from the Netherlands Cancer Registry and the Dutch Nationwide Pathology Database (2009-2019). R0 resection was defined as > 1 mm tumor clearance at the pancreatic, posterior, and vascular resection margins. Completeness of pathology reporting was scored on the basis of six elements: histological diagnosis, tumor origin, radicality, tumor size, extent of invasion, and lymph node examination. RESULTS: Among 2955 patients after PD for pancreatic cancer, the R0 resection rate was 49%. The R0 resection rate decreased from 68 to 43% (2009-2019, P < 0.001). The extent of resections in high-volume hospitals, minimally invasive surgery, neoadjuvant therapy, and complete pathology reports all significantly increased over time. Only complete pathology reporting was independently associated with lower R0 rates (OR 0.76, 95% CI 0.69-0.83, P < 0.001). Higher hospital volume, neoadjuvant therapy, and minimally invasive surgery were not associated with R0. R0 resection remained independently associated with improved overall survival (HR 0.72, 95% CI 0.66-0.79, P < 0.001), as well as in the 214 patients after neoadjuvant treatment (HR 0.61, 95% CI 0.42-0.87, P = 0.007). CONCLUSIONS: The nationwide rate of R0 resections after PD for pancreatic cancer decreased over time, mostly related to more complete pathology reporting. R0 resection remained associated with overall survival.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pancreaticoduodenectomía Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pancreaticoduodenectomía Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos